MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind Corp MNKD
$3.34
▲ +1.52%
(+$0.05)
⬆️ Above Yest. High
Open
$3.32
Prev Close
$3.29
Day Range
$3.17 – $3.39
52W Range
$2.23 – $6.51
Market Cap
$1.07B
P/E (TTM)
181.53
Beta
1.11
EPS (TTM)
$-0.14
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-07-28 |
| Shares Out. | 319,390,000 |
| Website | mannkindcorp.com/ ↗ |
| Phone | 18009279800 |
| Employees | 592 |
| Revenue | $109.4M |
| Gross Profit | $79.8M |
| Net Income | -$19.0M |
| Free Cash Flow | -$18.1M |
| Total Assets | $732.3M |
| Total Liabilities | $799.5M |
| Equity | -$67.2M |
About MannKind Corp
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
MannKind Corp is a publicly traded company under the ticker symbol MNKD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)